Researchers at Cold Spring Harbor Laboratory have discovered that the enzyme PTP1B contributes to memory decline in Alzheimer's disease. Reducing PTP1B activity may enhance the function of immune cells in clearing amyloid-β plaques, potentially leading to new treatment approaches. The study suggests combining existing drugs with PTP1B inhibitors to slow disease progression and improve patient quality of life. Teljes cikk (Euronews.com)